These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 30642537)
1. Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo). Halmos B; Tan EH; Soo RA; Cadranel J; Lee MK; Foucher P; Hsia TC; Hochmair M; Griesinger F; Hida T; Kim E; Melosky B; Märten A; Carcereny E Lung Cancer; 2019 Jan; 127():103-111. PubMed ID: 30642537 [TBL] [Abstract][Full Text] [Related]
2. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Schuler M; Paz-Ares L; Sequist LV; Hirsh V; Lee KH; Wu YL; Lu S; Zhou C; Feng J; Ellis SH; Samuelsen CH; Tang W; Märten A; Ehrnrooth E; Park K; Yang JC Lung Cancer; 2019 Jul; 133():10-19. PubMed ID: 31200814 [TBL] [Abstract][Full Text] [Related]
3. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. Lu S; Shih JY; Jang TW; Liam CK; Yu Y Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350 [TBL] [Abstract][Full Text] [Related]
4. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Yang JC; Sequist LV; Zhou C; Schuler M; Geater SL; Mok T; Hu CP; Yamamoto N; Feng J; O'Byrne K; Lu S; Hirsh V; Huang Y; Sebastian M; Okamoto I; Dickgreber N; Shah R; Märten A; Massey D; Wind S; Wu YL Ann Oncol; 2016 Nov; 27(11):2103-2110. PubMed ID: 27601237 [TBL] [Abstract][Full Text] [Related]
5. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib. Yamamoto N; Mera T; Märten A; Hochmair MJ Adv Ther; 2020 Feb; 37(2):759-769. PubMed ID: 31863283 [TBL] [Abstract][Full Text] [Related]
6. Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib. Tamura K; Nukiwa T; Gemma A; Yamamoto N; Mizushima M; Ochai K; Ikeda R; Azuma H; Nakanishi Y Int J Clin Oncol; 2019 Aug; 24(8):917-926. PubMed ID: 30953238 [TBL] [Abstract][Full Text] [Related]
7. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T; Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992 [TBL] [Abstract][Full Text] [Related]
8. A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam. Pham CP; Nguyen TTH; Do AT; Nguyen TK; Hoang TAT; Le TA; Vuong DTH; Nguyen DNT; Dang VK; Nguyen TO; Pham VL; Nguyen MH; Vo THT; Do HK; Vu HT; Nguyen TTH; Pham VT; Trinh LH; Nguyen KD; Nguyen HG; Truong CM; Pham TMC; Nguyen TBP BMC Cancer; 2024 Feb; 24(1):176. PubMed ID: 38317094 [TBL] [Abstract][Full Text] [Related]
9. Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group. Agraso S; Lázaro M; Firvida XL; Santomé L; Fernández N; Azpitarte C; Leon L; Garcia C; Hudobro G; Areses MC; Campos B; Quiroga N; García J; Casal J Cancer Treat Res Commun; 2022; 33():100646. PubMed ID: 36335799 [TBL] [Abstract][Full Text] [Related]
10. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. Minegishi Y; Yamaguchi O; Sugawara S; Kuyama S; Watanabe S; Usui K; Mori M; Hataji O; Nukiwa T; Morita S; Kobayashi K; Gemma A BMC Cancer; 2021 Mar; 21(1):208. PubMed ID: 33648453 [TBL] [Abstract][Full Text] [Related]
11. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. Ho GF; Chai CS; Alip A; Wahid MIA; Abdullah MM; Foo YC; How SH; Zaatar A; Lam KS; Leong KW; Low JS; Yusof MM; Lee EC; Toh YY; Liam CK BMC Cancer; 2019 Sep; 19(1):896. PubMed ID: 31500587 [TBL] [Abstract][Full Text] [Related]
12. Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group. Sonehara K; Kobayashi T; Tateishi K; Morozumi N; Yoshiike F; Hachiya T; Ono Y; Takasuna K; Agatsuma T; Masubuchi T; Matsuo A; Tanaka H; Morikawa A; Hanaoka M; Koizumi T Thorac Cancer; 2019 May; 10(5):1078-1085. PubMed ID: 31006178 [TBL] [Abstract][Full Text] [Related]
13. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer. Tanaka H; Taima K; Itoga M; Ishioka Y; Baba K; Shiratori T; Sakamoto H; Tsuchiya J; Nakagawa H; Hasegawa Y; Yasugahira H; Okudera K; Takanashi S; Tasaka S Med Oncol; 2019 May; 36(6):57. PubMed ID: 31089973 [TBL] [Abstract][Full Text] [Related]
14. Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. Choi MK; Ahn JS; Kim YC; Cho BC; Oh IJ; Kim SW; Lee JS; Kim JH; Ahn MJ; Park K Lung Cancer; 2018 May; 119():36-41. PubMed ID: 29656750 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam. Vu TH; Nguyen HTT; Dao LK; Duong CK; Nguyen CV; Doan TT; Nguyen HTT; Hoang HH; Dinh DK; Le GV; Vu TT; Truong MC; Nguyen LT Asian Pac J Cancer Prev; 2021 May; 22(5):1581-1590. PubMed ID: 34048189 [TBL] [Abstract][Full Text] [Related]
16. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. Schuler M; Tan EH; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; Yang JC; Lee KH; Lu S; Shi Y; Kim SW; Laskin J; Kim DW; Arvis CD; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K J Cancer Res Clin Oncol; 2019 Jun; 145(6):1569-1579. PubMed ID: 30783814 [TBL] [Abstract][Full Text] [Related]
17. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Wu YL; Sequist LV; Tan EH; Geater SL; Orlov S; Zhang L; Lee KH; Tsai CM; Kato T; Barrios CH; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin Yang J; Paz-Ares L; Park K Clin Lung Cancer; 2018 Jul; 19(4):e465-e479. PubMed ID: 29653820 [TBL] [Abstract][Full Text] [Related]
18. Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience. Ezeife DA; Melosky B; Tudor R; Lin S; Lau A; Panzarella T; Leighl NB Curr Oncol; 2018 Oct; 25(5):e385-e390. PubMed ID: 30464688 [TBL] [Abstract][Full Text] [Related]
19. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Hochmair MJ; Morabito A; Hao D; Yang CT; Soo RA; Yang JC; Gucalp R; Halmos B; Wang L; Golembesky A; Märten A; Cufer T Future Oncol; 2018 Nov; 14(27):2861-2874. PubMed ID: 30336693 [TBL] [Abstract][Full Text] [Related]
20. Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study. Brueckl WM; Reck M; Schäfer H; Neben K; Griesinger F; Rawluk J; Krüger S; Kokowski K; Ficker JH; Möller M; Schueler A; Laack E J Geriatr Oncol; 2023 Jan; 14(1):101394. PubMed ID: 36323612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]